NCT03885128

Brief Summary

Chronic Obstructive Pulmonary Disease (COPD) is the fourth-leading cause of death. It is a progressive illness that requires life-long treatment.Promoting airway clearance (AC) using mucolytics together with airway clearance techniques (ACTs) form the basis for pulmonary therapy in COPD care.Therefore, new airway clearance modalities are required to decrease the detrimental effects of accumulated secretions in COPD. One of the devices used in AC is the high frequency chest wall oscillation (The Vest). HFCWO involves the use of an inflatable vest/jacket that covers the chest and is attached to an air pulse-generating compressor which rapidly inflates and deflates the vest, producing oscillations to the chest wall of 5-25 Hz. Another new airway clearance modality is oscillating positive expiratory pressure(Quake) which combines PEP therapy with high frequency oscillations.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P50-P75 for not_applicable chronic-obstructive-pulmonary-disease

Timeline
Completed

Started Nov 2017

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2017

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

March 18, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 21, 2019

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2019

Completed
29 days until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2019

Completed
Last Updated

August 30, 2023

Status Verified

August 1, 2023

Enrollment Period

1.5 years

First QC Date

March 18, 2019

Last Update Submit

August 28, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • Pulmonary function test (spirometry)

    * it measure ventilatory functions. * Then the patients sat comfortably and upright while putting the nose clip and relax. * The patient was asked to inhale as deeply as possible, hold the breath, and then inserted the mouthpiece carefully into the mouth. * The patient held the mouthpiece tightly between the lips, and kept tongue down. * The patient was asked to exhale for as long as possible and blow for at least 6 seconds.

    Before and 6 weeks

Secondary Outcomes (1)

  • impulse oscillometry

    before and 6 weeks

Study Arms (2)

Vest arm

EXPERIMENTAL

high frequency chest wall oscillation vest performed 4 times per week for 6 successive weeks for 30 patients

Device: High frequency extra thoracic oscillations vest

Quake arm

EXPERIMENTAL

Vibratory positive expiratory pressure quake performed 4 times per week for 6 successive weeks for 30 patients

Device: Intrathoracic oscillatory quake

Interventions

Oscillations applied extra thoracic through vest device aiming for airway clearance

Vest arm

Oscillation introduced intrathoracic through quake device through placing quake in mouth and ordering patient to breathing to move secretions

Quake arm

Eligibility Criteria

Age45 Years - 72 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • All patients were diagnosed by chest physician based on the modified criteria defined in the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines 2017.
  • All patients were diagnosed as COPD for at least two years.
  • All Patients must use their prescribed medications.

You may not qualify if:

  • All patients that had one of the following were excluded from the study. History of osteoporosis, significant gastro-esophageal reflux, hiatus hernia. Recent acute cardiac event (6 weeks) or congestive cardiac failure. Any significant musculoskeletal disorders. Presence of active hemoptysis Presence of malignant disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Faculty of physical therapy

Dokki, Giza Governorate, 12613, Egypt

Location

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive

Condition Hierarchy (Ancestors)

Lung Diseases, ObstructiveLung DiseasesRespiratory Tract DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Nagwa M Badr, Professor

    Professor physical therapy at Cairo university

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

March 18, 2019

First Posted

March 21, 2019

Study Start

November 1, 2017

Primary Completion

May 1, 2019

Study Completion

May 30, 2019

Last Updated

August 30, 2023

Record last verified: 2023-08

Locations